



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



kb-NB77-78

Item No. 21562

CAS Registry No.: 1350622-33-1
Formal Name: 9-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-b]pyridin-5-one
MF: C₁₈H₂₅NO₃Si
FW: 331.5
Purity: ≥98%
UV/Vis.: λ_{max}: 214, 252, 346 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

kb-NB77-78 is supplied as a crystalline solid. A stock solution may be made by dissolving the kb-NB77-78 in the solvent of choice, which should be purged with an inert gas. kb-NB77-78 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of kb-NB77-78 in these solvents is approximately 20, 25, and 30 mg/ml, respectively.

kb-NB77-78 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, kb-NB77-78 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. kb-NB77-78 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

kb-NB77-78 is an inactive analog of the protein kinase D (PKD) inhibitor CID755673 (Item No. 15924).¹ It does not bind PKD1 in a fluorescence polarization assay and has no effect on PKD1 phosphorylation in LNCaP cancer cells.

Reference

1. George, K.M., Frantz, M.C., Bravo-Altamirano, K., *et al.* Design, synthesis, and biological evaluation of PKD inhibitors. *Pharmaceutics* **3**(2), 186-228 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/07/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM